Research programme: capillary stem cells - Asahikawa Medical University/Asubio Pharma
Latest Information Update: 07 Jun 2016
At a glance
- Originator Asahikawa Medical University; Asubio Pharma
- Developer Asubio Pharma
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Cardiovascular disorders